Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rome – page 59

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rome at a glance
2 209
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 209 trials in Rome

Open in trial search

Malignant peritoneal neoplasm+2

Recruiting

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Pneumonia

Recruiting

Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baloxavir Marboxil
  • Sponsor:University Of Oxford

Psychotic disorder+1

Recruiting

Study on Long-Term Safety of KarXT (Trospium Chloride, Xanomeline Tartrate) for Patients with Alzheimer's-Related Psychosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Karuna Therapeutics Inc.

Myocarditis+2

Recruiting

Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Antwerp University Hospital

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma Services AG

Endometrial cancer+3

Recruiting

Study of E7386 and Lenvatinib for Patients with Liver, Colon, Endometrial, or Other Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

Bladder transitional cell carcinoma+3

Recruiting

Study on Hexaminolevulinate for Patients with Non-Muscle Invasive Bladder Cancer to Reduce Need for Second Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Hexaminolevulinate
  • Sponsor:Universita Degli Studi Di Roma La Sapienza

Glioblastoma

Recruiting

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Pruritus

Recruiting

Study on the Effectiveness and Safety of Dupilumab for Adults with Chronic Itch of Unknown Cause

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Systemic scleroderma+1

Recruiting

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

  • Pulmonary function assessment
  • Disease exacerbation prevention
  • RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

  • Targeted molecular therapies
  • Combination treatment approaches
  • Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

  • Early disease intervention
  • Stroke treatment optimization
  • Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

  • Immune system modulation
  • Novel biological therapies
  • Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.